HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report)'s stock had its "neutral" rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $1.00 price objective on the stock. HC Wainwright's price objective points to a potential downside of 14.16% from the company's previous close.

Separately, Bank of America lowered Lyell Immunopharma from a "buy" rating to an "underperform" rating and reduced their target price for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th.

Lyell Immunopharma Trading Down 3.7 %

Lyell Immunopharma stock traded down $0.05 during trading hours on Tuesday, hitting $1.17. 1,111,451 shares of the stock traded hands, compared to its average volume of 1,001,950. The company has a market cap of $298.24 million, a PE ratio of -1.37 and a beta of -0.47. Lyell Immunopharma has a one year low of $0.85 and a one year high of $3.26. The firm's 50-day moving average price is $1.22 and its two-hundred day moving average price is $1.70.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 33.54% and a negative net margin of 323,792.09%. The firm had revenue of $0.03 million for the quarter. On average, sell-side analysts expect that Lyell Immunopharma will post -0.85 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Lyell Immunopharma in the first quarter valued at about $64,000. Intech Investment Management LLC purchased a new stake in Lyell Immunopharma during the third quarter valued at about $52,000. Dimensional Fund Advisors LP raised its position in Lyell Immunopharma by 197.8% during the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company's stock valued at $58,000 after acquiring an additional 26,635 shares in the last quarter. ProShare Advisors LLC boosted its stake in Lyell Immunopharma by 9.3% during the first quarter. ProShare Advisors LLC now owns 48,986 shares of the company's stock worth $109,000 after buying an additional 4,170 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Lyell Immunopharma by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company's stock valued at $68,000 after buying an additional 19,287 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.